301 related articles for article (PubMed ID: 38251678)
1. Evolving landscape of treatments targeting the microenvironment of liver metastases in non-small cell lung cancer.
Zhu L; Yu X; Tang X; Hu C; Wu L; Liu Y; Zhou Q
Chin Med J (Engl); 2024 May; 137(9):1019-1032. PubMed ID: 38251678
[TBL] [Abstract][Full Text] [Related]
2. Stereotatic radiotherapy in metastatic non-small cell lung cancer: Combining immunotherapy and radiotherapy with a focus on liver metastases.
Corrao G; Marvaso G; Ferrara R; Lo Russo G; Gugliandolo SG; Piperno G; Spaggiari L; De Marinis F; Orecchia R; Garassino MC; Jereczek-Fossa BA
Lung Cancer; 2020 Apr; 142():70-79. PubMed ID: 32120227
[TBL] [Abstract][Full Text] [Related]
3. Organ-specific immune checkpoint inhibitor treatment in lung cancer: a systematic review and meta-analysis.
Yu S; Zhang S; Xu H; Yang G; Xu F; Yang L; Chen D; An G; Wang Y
BMJ Open; 2023 Mar; 13(3):e059457. PubMed ID: 36931679
[TBL] [Abstract][Full Text] [Related]
4. Synergizing systemic responses by combining immunotherapy with radiotherapy in metastatic non-small cell lung cancer: The potential of the abscopal effect.
Theelen WS; de Jong MC; Baas P
Lung Cancer; 2020 Apr; 142():106-113. PubMed ID: 32126451
[TBL] [Abstract][Full Text] [Related]
5. Immune suppressive microenvironment in liver metastases contributes to organ-specific response of immunotherapy in advanced non-small cell lung cancer.
Deng JY; Gou Q; Yang L; Chen ZH; Yang MY; Yang XR; Yan HH; Wei XW; Liu JQ; Su J; Zhong WZ; Xu CR; Wu YL; Zhou Q
J Immunother Cancer; 2023 Jul; 11(7):. PubMed ID: 37463790
[TBL] [Abstract][Full Text] [Related]
6. Recent advances in tumor microenvironment-targeted nanomedicine delivery approaches to overcome limitations of immune checkpoint blockade-based immunotherapy.
Kim J; Hong J; Lee J; Fakhraei Lahiji S; Kim YH
J Control Release; 2021 Apr; 332():109-126. PubMed ID: 33571549
[TBL] [Abstract][Full Text] [Related]
7. Complete, Unpredictable, Multi-site Response Including Brain and Liver Metastases in a Patient With RET-rearranged Non-small-cell Lung Cancer Treated With Single-agent Immunotherapy: A Case Report.
Riudavets M; Caramella C; Pradere P; Naltet C; Le Pechoux C; Adam J; Mabille L; Rouleau E; Besse B; Planchard D
Clin Lung Cancer; 2021 Mar; 22(2):e215-e219. PubMed ID: 33187915
[No Abstract] [Full Text] [Related]
8. Bone Metastasis and Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer (NSCLC): Microenvironment and Possible Clinical Implications.
Del Conte A; De Carlo E; Bertoli E; Stanzione B; Revelant A; Bertola M; Spina M; Bearz A
Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35743275
[TBL] [Abstract][Full Text] [Related]
9. The Impact of NOTCH Pathway Alteration on Tumor Microenvironment and Clinical Survival of Immune Checkpoint Inhibitors in NSCLC.
Li X; Wang Y; Li X; Feng G; Hu S; Bai Y
Front Immunol; 2021; 12():638763. PubMed ID: 34305884
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy in NSCLC patients with brain metastases. Understanding brain tumor microenvironment and dissecting outcomes from immune checkpoint blockade in the clinic.
Vilariño N; Bruna J; Bosch-Barrera J; Valiente M; Nadal E
Cancer Treat Rev; 2020 Sep; 89():102067. PubMed ID: 32682248
[TBL] [Abstract][Full Text] [Related]
11. Chemotherapy-induced immunomodulation in non-small-cell lung cancer: a rationale for combination chemoimmunotherapy.
Zheng H; Zeltsman M; Zauderer MG; Eguchi T; Vaghjiani RG; Adusumilli PS
Immunotherapy; 2017 Sep; 9(11):913-927. PubMed ID: 29338609
[TBL] [Abstract][Full Text] [Related]
12. Molecular Pathways: Targeting the Microenvironment of Liver Metastases.
Milette S; Sicklick JK; Lowy AM; Brodt P
Clin Cancer Res; 2017 Nov; 23(21):6390-6399. PubMed ID: 28615370
[TBL] [Abstract][Full Text] [Related]
13. Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015.
Ascierto PA; Agarwala S; Botti G; Cesano A; Ciliberto G; Davies MA; Demaria S; Dummer R; Eggermont AM; Ferrone S; Fu YX; Gajewski TF; Garbe C; Huber V; Khleif S; Krauthammer M; Lo RS; Masucci G; Palmieri G; Postow M; Puzanov I; Silk A; Spranger S; Stroncek DF; Tarhini A; Taube JM; Testori A; Wang E; Wargo JA; Yee C; Zarour H; Zitvogel L; Fox BA; Mozzillo N; Marincola FM; Thurin M
J Transl Med; 2016 Nov; 14(1):313. PubMed ID: 27846884
[TBL] [Abstract][Full Text] [Related]
14. Pan-Cancer Analysis Identifies Liver Metastases as Negative Predictive Factor for Immune Checkpoint Inhibitors Treatment Outcome.
Chen XJ; Ren A; Zheng L; Zheng ED; Jiang T
Front Immunol; 2021; 12():651086. PubMed ID: 34248939
[TBL] [Abstract][Full Text] [Related]
15. Induction PD-1 inhibitor toripalimab plus chemotherapy followed by concurrent chemoradiotherapy and consolidation toripalimab for bulky locally advanced non-small-cell lung cancer: protocol for a randomized phase II trial (InTRist study).
Wang Y; Deng L; Wang J; Zhang T; Wang W; Wang X; Liu W; Wu Y; Lv J; Feng Q; Zhou Z; Wang J; Wang L; Wang Z; Bi N
Front Immunol; 2023; 14():1341584. PubMed ID: 38288117
[TBL] [Abstract][Full Text] [Related]
16. Targeting Immunometabolism Mediated by CD73 Pathway in
Passarelli A; Aieta M; Sgambato A; Gridelli C
Front Immunol; 2020; 11():1479. PubMed ID: 32760402
[TBL] [Abstract][Full Text] [Related]
17. The effect of liver metastasis on efficacy of immunotherapy plus chemotherapy in advanced lung cancer.
Qin BD; Jiao XD; Liu J; Liu K; He X; Wu Y; Ling Y; Duan XP; Qin WX; Wang Z; Zang YS
Crit Rev Oncol Hematol; 2020 Mar; 147():102893. PubMed ID: 32065969
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic Implications of Tumor Microenvironment in Lung Cancer: Focus on Immune Checkpoint Blockade.
Genova C; Dellepiane C; Carrega P; Sommariva S; Ferlazzo G; Pronzato P; Gangemi R; Filaci G; Coco S; Croce M
Front Immunol; 2021; 12():799455. PubMed ID: 35069581
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms of drug resistance to immune checkpoint inhibitors in non-small cell lung cancer.
Zhou K; Li S; Zhao Y; Cheng K
Front Immunol; 2023; 14():1127071. PubMed ID: 36845142
[TBL] [Abstract][Full Text] [Related]
20. Molecular basis and rationale for combining immune checkpoint inhibitors with chemotherapy in non-small cell lung cancer.
Leonetti A; Wever B; Mazzaschi G; Assaraf YG; Rolfo C; Quaini F; Tiseo M; Giovannetti E
Drug Resist Updat; 2019 Sep; 46():100644. PubMed ID: 31585395
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
